TY - JOUR
T1 - Wy-48,252 (1,1,1-trifluoro-N-[3-(2-quinolinylmethoxy)phenyl]methane sulfonamide), an orally active leukotriene antagonist
T2 - effects on arachidonic acid metabolism in various inflammatory cells
AU - Chang, Joseph
AU - Borgeat, Pierre
AU - Schleimer, Robert P.
AU - Musser, John H.
AU - Marshall, Lisa A.
AU - Hand, James M.
PY - 1988/3/22
Y1 - 1988/3/22
N2 - The LTD4 antagonist, Wy-48,252 (1,1,1-trifluoro-N-[3-(2-quinolinylmethoxy)phenyl]methanesulfonamide), was assessed for its ability to modulate arachidonic acid metabolism in several inflammatory cells. In A23187-stimulated rat neutrophils. Wy-48,252 effectively inhibited the conversion of exogenous [14C]arachidonic acid to radiolabeled 5-hydroxyeicosatetraenoic acid (5-HETE) and thrombaxane B2 (TxB2) (IC50 = 2 and 9.1 μM, respectively). Synthesis of immunoreactive leukotriene B4 (LTB4) (IC50 = 4.6 μM) and TxB2 (IC50 = 3.3 μM) from endogenous substrate by these cells in the absence of [14C]arachidonic acid was similarly reduced. Wy-48,252 also reduced leukotriene C4 (LTC4) and PGE2 synthesis by zymosan-activated mouse peritonel macrophages (IC50 = 4.4 and 4.3 μM, respectively). 5-Lipoxygenase (5-LO) catalyzed reactions in human neutrophils, lung mast cells and basophils activated by various stimuli were dose dependently inhibited by Wy-48,252 while PGD2 synthesis by lung mast cells was inhibited at 100 μM. By contrast, 12-LO, 15-LO, phosphodiesterase activity and histamine release from mast cells and basophils were unaffected by Wy-48,252. These data suggested that the LTD4 antagonist, Wyy-48,252, also inhibited the synthesis of eicosanoids, a feature that may contribute to its pharmacological actions in vivo.
AB - The LTD4 antagonist, Wy-48,252 (1,1,1-trifluoro-N-[3-(2-quinolinylmethoxy)phenyl]methanesulfonamide), was assessed for its ability to modulate arachidonic acid metabolism in several inflammatory cells. In A23187-stimulated rat neutrophils. Wy-48,252 effectively inhibited the conversion of exogenous [14C]arachidonic acid to radiolabeled 5-hydroxyeicosatetraenoic acid (5-HETE) and thrombaxane B2 (TxB2) (IC50 = 2 and 9.1 μM, respectively). Synthesis of immunoreactive leukotriene B4 (LTB4) (IC50 = 4.6 μM) and TxB2 (IC50 = 3.3 μM) from endogenous substrate by these cells in the absence of [14C]arachidonic acid was similarly reduced. Wy-48,252 also reduced leukotriene C4 (LTC4) and PGE2 synthesis by zymosan-activated mouse peritonel macrophages (IC50 = 4.4 and 4.3 μM, respectively). 5-Lipoxygenase (5-LO) catalyzed reactions in human neutrophils, lung mast cells and basophils activated by various stimuli were dose dependently inhibited by Wy-48,252 while PGD2 synthesis by lung mast cells was inhibited at 100 μM. By contrast, 12-LO, 15-LO, phosphodiesterase activity and histamine release from mast cells and basophils were unaffected by Wy-48,252. These data suggested that the LTD4 antagonist, Wyy-48,252, also inhibited the synthesis of eicosanoids, a feature that may contribute to its pharmacological actions in vivo.
KW - 5-Lipoxygenase
KW - Cyclooxygenase
KW - LTD receptor
KW - Leukocytes
KW - Wy-48,252
UR - http://www.scopus.com/inward/record.url?scp=0023903043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023903043&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(88)90462-1
DO - 10.1016/0014-2999(88)90462-1
M3 - Article
C2 - 2454830
AN - SCOPUS:0023903043
SN - 0014-2999
VL - 148
SP - 131
EP - 141
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1
ER -